NCT00507936已完成2 期
A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain
AbbVie (prior sponsor, Abbott)49 个研究点 分布在 7 个国家目标入组 280 人开始时间: 2007年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 280
- 试验地点
- 49
- 主要终点
- Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP
研究概览
简要总结
This study will compare the efficacy and the safety of ABT-894 (1mg, 2mg or 4mg capsules) administered BID to placebo in the treatment of DNP. Another treatment arm will be Duloxetine 60mg administered once daily (QD). Approximately 275 subjects will be enrolled into the study at approximately 50 sites in both the United States and Europe. The study will be divided into the following periods: Screening/Washout (21 days) followed by a Baseline Visit, an 8-week Treatment Period and a 1-week Follow-up Visit.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •If female, subject is either postmenopausal for at least two (2) years or surgically sterile or is practicing at least one (1) method of birth control.
- •If female, subject must have negative results for pregnancy tests.
- •The subject must have a diagnosis of diabetes mellitus (Type 1 or Type 2) and a diagnosis of DNP.
- •Subject's DNP must be present for a minimum of six (6) months and should have begun in the feet with relative symmetrical onset.
- •Subject has an HgbA1c <=
- •Subjects who have an HgbA1c > 9 and <= 11 may be included in the study.
- •If male, the subject is surgically sterile (vasectomy), is sexually inactive, or is using a barrier method (condom) of birth control for the duration of the study and for 7 days following the last dose of study drug.
排除标准
- •The subject has failed previous treatment with duloxetine for DNP.
- •Subject has a diagnosis of narrow-angle glaucoma.
- •Subject has a history of an allergic reaction or intolerance to duloxetine, acetaminophen, or any other NNR agonist.
- •Subject has a diagnosis of fibromyalgia that requires treatment.
- •Subject has a functioning implanted medical device (spinal cord stimulator, intrathecal pump or peripheral nerve stimulator) for the treatment of neuropathic pain.
- •Subject has a history of seizures (febrile may be ok) or major depressive episode within the past two (2) years or major psychiatric disorder including bipolar disorder, schizophrenia or borderline personality disorder.
- •Subject has a history of myocardial infarction (MI) within six (6) months of the Screening Visit.
- •Subject has unstable angina.
- •Subject has ventricular arrhythmia requiring anti-arrhythmic therapy.
- •Subject has undergone a cardiac revascularization procedure within 30 days of Screening.
- •Subject has uncontrolled hypertension (HTN) defined as a systolic blood pressure (BP) >= 160 and/or a diastolic blood pressure (BP) >= 100 at Screening and/or Baseline.
- •Subject has a clinically significant abnormal ECG at Screening
- •Subject has an active malignancy of any type or has been diagnosed with or treated for cancer within the past 5 years.
- •Subject has a positive result for drugs of abuse at Screening with the exception of a positive result for a known prescribed medication.
- •Subject's screening laboratory results show hepatitis A, B or C.
- •Subject has a known or suspected history of Human Immunodeficiency Virus (HIV).
研究组 & 干预措施
A
Experimental
ABT-894 1 mg BID
干预措施: ABT-894 (Drug)
B
Experimental
ABT-894 2 mg BID
干预措施: ABT-894 (Drug)
C
Experimental
ABT-894 4 mg BID
干预措施: ABT-894 (Drug)
D
Placebo Comparator
干预措施: placebo (Drug)
E
Active Comparator
Duloxetine 60 mg QD
干预措施: Duloxetine (Drug)
结局指标
主要结局
Efficacy of each ABT-894 dose (1 mg, 2 mg, or 4 mg BID) versus placebo in the treatment of pain due to DNP
时间窗: Change from baseline to final 24-hour average pain score
次要结局
- Proportions of treatment responders; subjects who complete treatment period with 30% improvement(From Baseline to final 24-hour average pain score)
- Mean of 24-hour worst pain severity, average of night pain, and average of morning pain measured by the 11-point Likert scale and from subject's daily diary(Weekly through treatment phase)
- Brief Pain Inventory (BPI) (short form) including Pain Severity(At each visit from Baseline to Week 8 visit)
- Clinician Global Impression: Severity (CGI-S) and Patient Global Impression: Change (PGI-C)(At each visit from Baseline to Week 8 visit)
研究者
研究点 (49)
Loading locations...
相似试验
已完成
3 期
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisPlaque PsoriasisNCT00570986AbbVie (prior sponsor, Abbott)1,465
已完成
2 期
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic TherapyRheumatoid ArthritisNCT01960855AbbVie276
已完成
2 期
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)Attention-Deficit/Hyperactivity DisorderNCT00391729Abbott221
终止
2 期
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's DiseaseCrohn's DiseaseNCT00562887Abbott246
终止
2 期
A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's DiseaseAlzheimer's DiseaseNCT00069849Abbott64